Codexis (CDXS) said Tuesday it has signed a non-exclusive commercial and manufacturing license agreement with Alphazyme, part of Maravai LifeSciences (MRVI), covering multiple enzymes from Codexis' life science enzyme portfolio.
The agreement includes licenses for the HiFi DNA Polymerase, HiTemp Reverse Transcriptase, HiRev Isothermal Polymerase and other enzymes previously directed towards genomics and diagnostics.
Codexis will receive sales-based royalties under the terms of the agreement, according to the company.
Price: 3.05, Change: -0.03, Percent Change: -0.97
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.